Peptide vaccine: Phase Ib started

CuraVac began the double-blind, placebo-controlled, European Phase Ib CV-0002 trial to evaluate 2 dose levels of subcutaneous CV-MG01 on days 1, 29 and 85 in about 32 adult patients. ...